Resources for Innovators - A Supplier Expo and Pitch Event (Boston, MA)

Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

As the world’s largest provider of biopharmaceutical development and commercial outsourcing services, Quintiles offers an array of solutions and services for innovators that are designed to improve our customers’ probability of success in developing their therapies.

Through a combination of global capabilities and programs designed to fit the needs of newly launched and emerging biopharma companies, Quintiles can provide optimal solutions tailored to the specific needs of each customer.  This combination provides us with a flexible platform from which we can design and deliver the most effective strategy for leveraging the resources of the world’s leading CRO through a dedicated study team.

Our first service offering for innovators is our Emerging Biopharma (EBP) solution.  Designed to fit the specific needs of the emerging biopharma customer, Quintiles EBP services provide the nimble processes, streamlined team structure, and financial efficiency that innovator companies need to advance their therapies effectively. 

Our Emerging Biopharma solution provides the right model for each customer, delivered through dedicated project leaders and supported by executive sponsorship and the leading data system in the industry.  Using our global recruitment capabilities and broad therapeutic expertise within our 13 Centers of Excellence, Quintiles can help our customers design the model that fits the needs and the budgets of innovator companies.

Our second service offering for innovators is centered with our Early Clinical Development (ECD) Services group.  With Phase 1 units in both the US (Overland Park, KS) and the EU (London), Quintiles provides the scientific and operational expertise, flexible site capacity, and full-service clinical capabilities to effectively run an emerging biopharma’s early phase studies.  We excel in conducting First-in-Human (FIH) and complex Phase 1 studies, and we have been recognized as the leading Phase 1 CRO over the past 2 years in a leading industry survey.

Quintiles’ ECD group offers the best of both worlds for an innovator company—a small, dedicated team of Phase 1 experts to run the daily activities of the trial, supported by the most extensive scientific, regulatory and operational resources in the industry.  This combination provides for both ongoing work and long-term strategy to support the development of your compound.

Our third service offering for innovators involves the convergence of our clinical and commercial services at a very early stage of a drug’s development.   By engaging our commercial teams as early as the pre-clinical phase, we help our customers develop an integrated, optimized strategy for aligning the clinical development strategy in support of their asset strategy.  As the market for new pharmaceuticals becomes increasingly complex, it is more important than ever to understand the market potential for new therapies in order to maximize their value.  Utilizing our commercial insights to provide an accurate market assessment, Quintiles works with innovator companies to help them develop their asset strategy, including their product value proposition and stakeholder analysis and strategy.  From this point, our teams will coordinate to develop a commercially optimized clinical plan, and ultimately a Go-to-Market Strategy.

Our fourth service offering is our global, comprehensive and expanding laboratory capabilities.  For our newly launched innovator customers, Quintiles offers full-service genomics and bioanalytical (BA) analysis capabilities to support their early phase work.  As our customers progress in their development plan, our BA labs and global central laboratory network can provide the sample analysis and biomarker development that they need to continue in the evaluation of their products.

Our fifth service offering for innovator companies is our superior, industy-leading data capabilities.  Powered by the Infosario™ platform, Quintiles can harmomize clinical trial management data, electronic data capture, lab results, financial information and many other sources of data, including historical data from other trials, even if Quintiles was not involved with that study.  Infosario™ provides a truly integrated and streamlined approach to all of your data, allowing the innovator company to optimize its plans for study design, portfolio strategy and study execution.  Utilizing the robust strength of Infosario™, our customers can access the fullest possible picture of their drug development process, providing for proactive and improved safety, quality and efficiency across their development portfolio.

With our unmatched therapeutic expertise, our operational excellence and our global resources, Quintiles offers adaptable solutions to innovator companies who are looking for a quality research partner to support their development plans.  We can provide the optimal strategy for increasing your probability for success, delivered by experienced, right-sized teams that understand the demands of the innovator and emerging biopharma markets.